Plasma Concentrations of BDNF and IGF-1 in Abstinent Cocaine Users with High Prevalence of Substance Use Disorders: Relationship to Psychiatric Comorbidity

Maria Pedraz1*, Ana Isabel Martin-Velasco2*, Nuria Garcia-Marchena1*, Pedro Araos1, Antonia Serrano1, Pablo Romero-Sanchiz1, Juan Suarez1, Estela Castilla-Ortega1, Vicente Barrios3,4, Rafael Campos-Cloute5, Juan Jesus Ruiz7, Marta Torrens8,9,10, Julie Ann Chowen3,4,5, Jesus Argente3,4,5, Rafael de la Torre5,6,11, Luis Javier Santin12, Maria Angeles Villanua2, Fernando Rodriguez de Fonseca1,5*, Francisco Javier Pavon1*

1 Unidad Gestión Clínica de Salud Mental, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Regional Universitario de Málaga-Universidad de Málaga, Málaga, Spain, 2 Department of Physiology, Faculty of Medicine, Complutense University of Madrid, Madrid, Spain, 3 Department of Pediatrics & Pediatric Endocrinology, Hospital Infantil Universitario Niño Jesús, Instituto de Investigación La Princesa, Madrid, Spain, 4 Department of Pediatrics, Universidad Autónoma de Madrid, Madrid, Spain, 5 Centro de Investigación Biomédica en Red de la Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain, 6 Centro de Tratamiento Ambulatorio Mijas Costa-Diputación de Málaga, Mijas, Spain, 7 Centro Provincial de Drogodependencia-Diputación de Málaga, Málaga, Spain, 8 Neurociences Program, Institut Hospital del Mar d’Investigacions Mèdiques (IMIM), Barcelona, Spain, 9 Institut de Neuropsiquiatria i Addiccions (INAD) del Parc de Salut MAR, Barcelona, Spain, 10 Department of Psychiatry. Universitat Autònoma de Barcelona (UAB), Barcelona, Spain, 11 Facultat de Ciencies de la Salut i de la Vida, Universitat Pompeu Fabra (CEXS-UPF), Barcelona, Spain, 12 Departamento de Psicobiología y Metodología de las Ciencias del Comportamiento, Facultad de Psicología, Universidad de Málaga, Málaga, Spain

* These authors contributed equally to this work.

Abstract

Recent studies have identified biomarkers related to the severity and pathogenesis of cocaine addiction and common comorbid psychiatric disorders. Monitoring these plasma mediators may improve the stratification of cocaine users seeking treatment. Because the neurotrophic factors are involved in neural plasticity, neurogenesis and neuronal survival, we have determined plasma concentrations of brain-derived neurotrophic factor (BDNF), insulin-like growth factor 1 (IGF-1) and IGF-1 binding protein 3 (IGFBP-3) in a cross-sectional study with abstinent cocaine users who sought outpatient treatment for cocaine (n = 100) and age/body mass matched controls (n = 85). Participants were assessed with the diagnostic interview ‘Psychiatric Research Interview for Substance and Mental Disorders’. Plasma concentrations of these peptides were not different in cocaine users and controls. They were not associated with length of abstinence, duration of cocaine use or cocaine symptom severity. The pathological use of cocaine did not influence the association of IGF-1 with age observed in healthy subjects, but the correlation between IGF-1 and IGFBP-3 was not significantly detected. Correlation analyses were performed between these peptides and other molecules sensitive to addiction: BDNF concentrations were not associated with...
inflammatory mediators, lipid derivatives or IGF-1 in cocaine users, but correlated with che-
mokines (fractalkine/CX3CL1 and SDF-1/CXCL12) and N-acyl-ethanolamines (N-palmit-
toyl-, N-oleoyl-, N-arachidonoyl-, N-linoleoyl- and N-dihomo-γ-linolenoyl-ethanolamine) in
controls; IGF-1 concentrations only showed association with IGFBP-3 concentrations in
controls; and IGFBP-3 was only correlated with N-stearoyl-ethanolamine concentrations in
cocaine users. Multiple substance use disorders and life-time comorbid psychopathologies
were common in abstinent cocaine users. Interestingly, plasma BDNF concentrations were
exclusively found to be decreased in users diagnosed with both primary and cocaine-
induced disorders for mood and anxiety disorders. In summary, BDNF, IGF-1 and IGFBP-3
were not affected by a history of pathological use of cocaine supported by the absence of
associations with other molecules sensitive to cocaine addiction. However, BDNF was af-
fected by comorbid mood disorders. Further research is necessary to elucidate the role of
BDNF and IGF-1 in the transition to cocaine addiction and associated
psychiatric comorbidity.

Introduction

Chronic cocaine use induces long-lasting neurochemical, structural and behavioral adaptive
changes thought to result from altered gene and protein expression within cerebral areas play-
ing a critical role in addiction and reward [1]. Some of these changes are not fully reversed
upon prolonged abstinence, and may represent an example of aberrant cocaine-induced neuro-
plastic changes related to cocaine dependence and an increased susceptibility to relapse to drug
taking even after a long period of abstinence [2,3].

Furthermore, long-term cocaine use is commonly associated with altered executive func-
tions, impaired emotional processing capacity and a higher incidence of comorbid mental dis-
orders, particularly mood and anxiety disorders [4,5,6]. The diagnosis of psychiatric
comorbidity is an important consideration for effective therapies to overcome cocaine addic-
tion. However, the accurate diagnosis of comorbid psychiatric disorders in cocaine addicts has
to face two major problems, the effects of cocaine can conceal symptoms of other mental disor-
ders and the diagnosis is defined by manifestations rather than by direct biomarkers [7,8].

Focusing on this last point, the search for peripheral biomarkers for both psychiatric and
substance use disorders has caused an increasing interest in addiction psychiatry research over
the last few years. This growing research has generated a number of putative biomarkers, main-
ly involving the immune system and inflammatory responses, which still require replication in
larger studies [9,10,11]. Recently, our group has studied the plasma profile of inflammatory
mediators and fatty acid derivatives in abstinent cocaine users under outpatient treatment
[12,13]. We found certain cytokines and chemokines that might serve as reliable biomarkers
for pathological use of cocaine (i.e., binge use and/or chronic use) and symptom severity [12].
Additionally, several fatty acid derivatives such as endocannabinoids and congeners were bio-
markers for cocaine use disorders and psychiatric comorbidity [13].

Neurotrophic factors are peptides that are known for their role in mediating neuronal plas-
ticity and neuronal growth. In addition to neurons, these factors are produced by other cells
and can affect and integrate neural, immune and endocrine systems. They have been reported
to mediate the effects of drugs for the treatment of mental disorders but also play a relevant
role in the acute and chronic responses produced by addictive drugs [14]. We have focused this
study on two trophic factors, which are found in plasma and involved in mediating neuronal plasticity, the brain-derived neurotrophic factor (BDNF) and the insulin-like growth factor 1 (IGF-1). In addition to IGF-1, we have also measured the IGF binding protein 3 (IGFBP-3) as relevant protein modulating its effects.

BDNF is a neurotrophin that participates in neuronal survival, differentiation, synaptogenesis and maintenance. Accumulating evidence suggests that alterations in the BDNF expression underlie a variety of psychiatric and neurological disorders. BDNF has been associated positively with some disorders (e.g., major depression and bipolar disorder) but there are also many non-specific or conflicting findings (schizophrenia and autism) [11,15]. Furthermore, BDNF has been also evaluated in cocaine addiction and comorbid disorders. Indeed, serum BDNF concentrations have been recently postulated as an indication of relapse risk during early recovery from cocaine dependence in a prospective study [16]. Another study performed by Corominas-Roso and colleagues showed that an increase in serum BDNF concentrations during early abstinence correlates with cocaine craving and abstinence symptoms [17], but interestingly these increased BDNF concentrations are not observed in patients displaying cocaine-induced psychosis [18].

IGF-1 is a trophic mediator regulated by growth hormone (GH) that may either be free or bound to binding proteins. IGFBP-3 is the most abundant binding protein in human blood and this complex prolongs the half-life of IGF-1. IGF-1 regulates proliferation, development and growth of neural cells (for recent reviews [19,20]). This peptide is also involved in the pathogenesis and evolution of psychiatric disorders in preclinical models [21,22] and clinical cases in old [23] and young [24] individuals. Thus, a cross-sectional study in older adults showed that the association between depressive symptoms and memory deficits is stronger with lower concentrations of circulating IGF-1 [23]. Young adults with GH deficiency exhibit anxious or depressed moods, which can be treated by GH therapy that increases IGF-1 concentrations. Furthermore, IGF-1 concentrations negatively correlate with depression, fatigue, tension and anxiety and positively with vigor and memory [24]. Regarding drugs of abuse in humans, IGF-1 concentrations have been assessed in alcohol and opiate dependence. Studies in alcohol dependents revealed a positive correlation between blood insulin level and alcohol craving, but not between alcohol craving and IGF-1 concentrations during either the active drinking phase or during abstinence [25]. In contrast to alcohol, serum IGF-1 is found to be elevated in opiate dependence [5].

The aim of the present cross-sectional study is to examine the plasma concentrations of BDNF, IGF-1 and IGFBP-3 in a cohort of abstinent cocaine users on an outpatient basis according to cocaine use history (duration of use, length of abstinence and cocaine symptom severity) and the comorbidity of other mental disorders. We found that plasma BDNF, IGF-1 and IGFBP-3 are unaltered in abstinent cocaine users but they are affected by the presence of comorbid mood and anxiety disorders.

Methods and Materials

1 Subjects and recruitment

All participants in the present cross-sectional study were white Caucasians grouped into abstinent cocaine users and healthy controls. One-hundred and ten cocaine users were enrolled from outpatient treatment programs for cocaine addiction in the province of Málaga (Spain) for a 36 month period (2011–2013). Eighty healthy individuals were recruited in parallel from a multidisciplinary staff working at the Hospital Regional Universitario de Málaga.

Cocaine users had to meet eligibility criteria based on inclusion and exclusion criteria. Inclusion criteria were as follows: ≥ 18 years to 65 years of age, intranasal cocaine use, diagnosis of a
lifetime ‘pathological use’ of cocaine (chronic intoxication and/or binge), and abstinence from cocaine for at least 2 weeks before testing. The ‘pathological use’ of cocaine was determined through a psychiatric interview, while the abstinence of cocaine users was checked weekly by urine analysis in the outpatient treatment centers for cocaine addiction and plasma analyses [12]. Exclusion criteria were as follows: personal history of chronic diseases (e.g. cardiovascular, respiratory, renal, hepatic, neurological or endocrine diseases), personal history of cancer, infectious diseases, incapacitating cognitive alterations and/or severe schizophrenia, and pregnancy.

Controls were matched with the cocaine group for age and body mass index (BMI) and they were required to be ≥18 years to 65 years of age. In addition to the mentioned exclusion criteria for abstinent cocaine users, controls were excluded with: personal history of drug abuse and lifetime psychiatric disorders.

2 Clinical assessments

All cocaine users were evaluated according to ‘Diagnostic and Statistical Manual of Mental Disorders-4th Edition-Text Revision’ (DSM-IV-TR) criteria, using the Spanish version of the ‘Psychiatric Research Interview for Substance and Mental Disorders’ (PRISM) [7,26]. Controls were initially evaluated by PRISM (for substance screening and abuse and dependence) and subsequently by the Spanish version of the ‘Composite International Diagnostic Interview’ (CIDI) for the detection of psychiatric disorders [27]. All the interviews were performed by experienced psychologists who had received both PRISM and CIDI training.

2.1 Psychiatric Research Interview for Substance and Mental Diseases (PRISM). The PRISM is a semi-structured interview that has demonstrated good psychometric properties in terms of test-retest reliability [28], inter-rater reliability [29] and validity [7] to diagnose psychiatric disorders among substance users.

Diagnoses were made using two time-frames: ‘current’ (criteria were met within the past year) and ‘past’ (criteria were met before the previous 12 months). Lifetime prevalence, taking into account both current and past diagnoses, was used to present the frequency of substance use disorders, non-substance use disorders and psychiatric comorbidity. In addition to the diagnoses of substance abuse and dependence, the PRISM differentiates ‘pathological use’ (chronic intoxication: substance use ≥4 days a week for ≥3 weeks; and/or binge use: ≥3 consecutive days of continuous substance use) from ‘occasional use’ (substance use less than 4 days a week, unless substance was used in a binge pattern).

The cocaine symptom severity was assessed combining the DSM-IV-TR criteria for cocaine use disorders: 7 dependence criteria (for diagnosis of dependence three or more co-occurring symptoms in a 12-month period are required); and 4 abuse criteria (one symptom is necessary for diagnosis of abuse), which is in agreement with the unidimensionality of DSM-5 criteria [30,31]. More details regarding analysis of cocaine symptom severity have been described previously (see [13]).

3 Laboratory methods for human samples

3.1 Collection and analysis of plasma samples. Blood samples were obtained in the morning (09:00–11:00 h AM) after fasting for 8–12 h (previous to the psychiatric interviews). Venous blood was collected into 10 mL K$_2$-EDTA tubes (BD, Franklin Lakes, NJ, USA) and processed to obtain plasma. Blood samples were centrifuged at 2,200×g for 15 min (4°C) and individually assayed for detecting infectious diseases by 3 rapid tests for HIV (Retroscreen HIV, QualPro Diagnostics-Tulip Group Ltd, Goa, India), hepatitis B (HBsAg Test, Toyo Diagnostics-Turklab Inc., Izmir, Turkey) and hepatitis C (Flaviscreen HCV, QualPro
Diagnostics-Tulip Group Ltd, Goa, India). Samples testing positive were discarded following safety protocols.

Plasma analyses for cocaine metabolite (Benzylecgonine Specific Direct ELISA Kit Immunoanalysis, Pomona, CA, USA) were performed to confirm cocaine abstinence. Four cocaine users who tested negative for drugs of abuse in urine analyses at the outpatient treatment centers for cocaine addiction were positive for benzylecgonine in plasma, and these cocaine users were excluded from this study. Plasma samples were stored at -80°C until further analyses.

3.2 Multiplex immunoassay analysis. A Bio-Plex Suspension Array System 200 (Bio-Rad Laboratories, Hercules, CA, USA) was used to quantify the plasma concentrations of anti- and pro-inflammatory cytokines, homeostatic and pro-inflammatory chemokines and BDNF following the manufacturer’s instructions as previously reported [12]. Human protein panels were used to simultaneously detect the following analytes: Tumor necrosis factor-alpha (TNFα); interleukin-1 beta (IL-1β); interleukin-6 (IL-6); interleukin-10 (IL-10); CX3CL1 [Chemokine (C-X3-C motif) ligand 1], commonly referred to as fractalkine; CCL2 [Chemokine (C-C motif) ligand 2], also referred to as monocyte chemotactic protein-1 (MCP-1); CXCL12 [Chemokine (C-X-C motif) ligand 12], also referred to stromal cell-derived factor-1 (SDF-1); and BDNF. Raw data (mean fluorescence intensity) were analyzed using the Bio-Plex Manager Software 4.1 (Bio-Rad Laboratories, Hercules, CA, USA). Data of plasma concentrations (pg of protein/mL) were used to perform multiple correlation studies and analyses of the means.

3.3 Radioimmunoassay analysis for IGF1 and IGFBP-3. Plasma concentrations of total IGF-1 were estimated by double antibody radioimmunoassay (RIA), after removal of serum IGFBPs by acid-ethanol extraction. To confirm the removal of IGFBPs, extracted and non-extracted plasma fractions were incubated with 125I-IGF-1 at 4°C for 24 h. Dextran charcoal was used to separate the bound and free tracers. The IGF-1 antiserum (UB2–495) was a gift from Drs Underwood and Van Wisk distributed by the Hormone Distribution Program of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) through the National Hormone and Pituitary Program. Concentrations of IGF-1 were expressed in terms of rat IGF-1 from Gropep Bioreagents Pty Ltd (Adelaide, SA, Australia). Test sensitivity was 10 ng/mL and the intra-assay coefficient of variation was 8%. All samples were run in the same batch.

Plasma IGFBP-3 concentration was determined in duplicate by RIA using a commercially available kit (Mediagnost GmbH, Reutlingen, Germany) following the manufacturer’s protocol. The assay sensitivity was 500 pg/mL and the intra-assay coefficient of variation was 7.5%.

3.4 Quantification of acyl derivatives. The following lipid derivatives and their respective deuterated forms were used for quantification: N-stearoyl-ethanolamine (SEA), N-palmitoyl-ethanolamine (PEA) and PEA-d4, N-oleoyl-ethanolamine (OEA) and OEA-d4, N-palmitoleoyl-ethanolamine (POEA), N-arachidonoyl-ethanolamine (AEA) and AEA-d4, N-linoleoyl-ethanolamine (LEA) and LEA-d4, N-docosahexaenoyl-ethanolamine (DHEA) and DHEA-d4, N-dihomo-γ-linolenoyl-ethanolamine (DGLEA), 2-arachidonoyl-glycerol (2-AG) and 2-AG-d4, and 2-linoleoyl-glycerol (2-LG). PEA-d4, OEA-d4 and AEA-d4 were used for quantification of POEA, SEA and DGLEA respectively, since their deuterated forms were not commercially available. All reagents were obtained from Cayman Chemical (Ann Arbor, MI, USA).

Sample extraction and the chromatographic separation were performed in a Liquid Chromatography-tandem Mass Spectrometry System (Agilent Technologies, Wilmington, DE, USA) as previously reported [13]. The tandem quadrupole mass spectrometer operated on the positive electrospray mode. The multiple reaction monitoring mode was used for the analysis with the following precursor to product ion transitions: m/z 328.1/62 for SEA, m/z 300.1/62 for PEA, m/z 304.4/66 for PEA-d4, m/z 326.1/62 for OEA, m/z 330.4/66 for OEA-d4, m/z 298.2/62 for POEA, m/z 348.3/62 for AEA, m/z 352.2/66 for AEA-d4, m/z 324.5/62 for LEA, m/z 328.5/62 for DGLEA. Hard copy of the figure was obtained from PLOS ONE, DOI:10.1371/journal.pone.0118610 March 3, 2015 5/20.
66 for LEA-d₄, m/z 372.6/62 for DHEA, m/z 376.3/66 for DHEA-d₄, m/z 350.2/62 for DGLEA, m/z 379.2/287 for 2-AG, m/z 384.3/287 for 2-AG-d₅ and m/z 355.2/263 for 2-LG. A six-point external calibration curve prepared in the mobile phase (10:90, A:B) and spiked with 0.4–25 ng of N-acyl-ethanolamines and 0.8–50 ng of 2-acyl-glycerols was used for the quantification. Data of plasma concentration (ng of acyl derivative/mL) were used to perform multiple correlation studies.

4 Ethics statement
Written informed consent was obtained from each subject after they had received a complete description of the present study and had been given the chance to discuss any questions or issues. The study and protocols for recruitment were approved by the Ethics Committee of the Hospital Regional Universitario de Málaga (07/19/2009 PND049/2009 and PI0228–2013; CEI Provincial de Málaga) and therefore were conducted in accordance with the Declaration of Helsinki (seventh revision in 2013, Fortaleza, Brazil).

5 Statistical analyses
All data for graphs and tables are expressed as number and percentage of subjects [n (%)] or mean and standard deviation (SD) of concentrations [mean (SD)]. The significance of differences in categorical variables was determined by using the Fisher’s exact test; while continuous variables were evaluated by different statistical approaches according to the number of comparisons and the distribution of variables. For comparisons of two groups, the Student’s t-test was used for normally distributed continuous variables and the Mann-Whitney U test was used as non-parametric test. For comparisons of three or more groups, one-way and analysis of variance (ANOVA) with Bonferroni correction for multiple comparisons was used for normal distributions whereas the Kruskal—Wallis analysis with the Dunn’s post test was used as non-parametric analysis. Correlation analyses were performed by using the Pearson’s correlation coefficient (r) for continuous variables with normal distribution and Spearman’s rank correlation coefficient (rho) for continuous variables without normality and discrete variables. The Holm-Bonferroni correction was employed for multiple comparisons of correlation coefficients for controlling the type I errors. The normal distribution of variables was evaluated using the D’Agostino & Pearson omnibus normality test. Thresholds of 0.05 were applied for p-values and adjusted p-values. Statistical analyses were performed using the computer program Graph-Pad Prism version 5.04 (GraphPad Software, San Diego, CA, USA).

Results
1 Sample demographics and clinical characteristics
A total of 185 subjects both sexes were selected for this study and grouped into the cocaine (n = 100) and control (n = 85) groups. The average participant was a 36–37 year-old male with a BMI of 26 (weighing 75–77 kg). A description of the sample is presented in Table 1.

Cocaine users displayed cocaine abstinence for 234.7 (436.3) days [mode: 30 days (range: 2,555)]. The percentages of cocaine users treated for substance use and psychological condition were 81.0% and 35.0% respectively. In contrast, only 17.6% of controls received psychological treatments.

Cocaine use disorders were the most prevalent lifetime substance use disorders (89%) followed by lifetime alcohol (64%), cannabis (23%), benzodiazepines (8%) and heroin (8%) use disorders (not including caffeine or nicotine).
Regarding common psychiatric disorders assessed with the PRISM, we found high prevalences of comorbid mood (33%), anxiety (22%), psychosis (13%) and personality (31%) disorders. Therefore, a vast majority of cocaine users who participated in this study were diagnosed with substance use disorders or multiple substance use disorders and psychiatric comorbidity.

2 Plasma concentrations of BDNF, IGF-1 and IGFBP-3

Mean plasma concentrations for BDNF, IGF-1 and IGFBP-3 were similar in both groups. The plasma concentrations of each protein were as follows: 274.9±200.3 pg/mL and 269.4±242.7 pg/mL for BDNF, 212.2±63.9 ng/mL and 210.7±51.2 ng/mL for IGF-1, and 3.91±0.94 μg/mL and 3.78±0.93 μg/mL for IGFBP-3, in the cocaine and control groups respectively.

2.1 Plasma concentrations of BDNF, IGF-1 and IGFBP-3 in relation to sex

As indicated in Fig. 1, we examined whether the sex composition in the cocaine and control groups affects the plasma concentrations of BDNF, IGF-1 and IGFBP-3. A two-way ANOVA was performed taking into consideration cocaine use and sex as factors. We did not observe main effects or interaction of these factors on the concentrations of BDNF, IGF-1 and IGFBP-3 between men and women in both groups.

2.2 Plasma concentrations of BDNF, IGF-1 and IGFBP-3 in relation to age

The influence of age on growth factors has been extensively described, especially with IGF-1 [33,34,35].

| VARIABLE | COCAINE GROUP | CONTROL GROUP | p-value |
|----------|---------------|---------------|---------|
| AGE (>18) [MEAN (SD)] | 35.8 (8.9) | 37.3 (10.7) | 0.299 a |
| SEX [n (%)] | Women 18 (18.0) | 25 (29.4) | 0.081 b |
| | Men 82 (82.0) | 60 (70.6) | |
| BODY MASS [MEAN (SD)] | Body Mass Index 25.5 (4.5) | 26.1 (4.0) | 0.343 a |
| | Weight (kg) 77.1 (14.4) | 75.3 (11.0) | 0.337 a |
| PSYCHOLOGICAL TREATMENT (EVER) [n (%)] | No 67 (67.0) | 80 (94.1) | <0.001 b |
| | Yes 35 (35.0) | 5 (5.9) | |
| SUBSTANCE USE TREATMENT (EVER) [n (%)] | No 21 (21.0) | 85 (100) | <0.001 b |
| | Yes 81 (81.0) | 0 (0.0) | |
| LIFETIME SUBSTANCE USE DISORDERS [n (%)] | Cocaine 89 (89.0) | - | - |
| | Alcohol 64 (64.0) | - | |
| | Cannabis 23 (23.0) | - | |
| | Benzodiazepines 8 (8.0) | - | |
| | Heroin 8 (8.0) | - | |
| | Hallucinogens 6 (6.0) | - | |
| | Others 7 (7.0) | - | |
| LIFETIME COCAINE USE DISORDERS [n (%)] | Abuse or Dependence 89 (89.0) | - | - |
| | Abuse 78 (78.0) | - | |
| | Dependence 84 (84.0) | - | |
| LIFETIME COMMON PSYCHIATRIC DISORDERS [n (%)] | Mood Disorders 33 (33.0) | - | - |
| | Anxiety Disorders 22 (22.0) | - | |
| | Psychosis Disorders 13 (13.0) | - | |
| | Personality Disorders 31 (31.0) | - | |

a p-value from Student’s t-test.
b p-value from Fisher’s exact test or Chi-square test.

doi:10.1371/journal.pone.0118610.t001
Figure 1

Fig 1. Plasma concentrations of BDNF, IGF-1 and IGFBP-3 according to sex in abstinent cocaine users and control subjects. A) BDNF (pg/mL); B) IGF-1 (ng/mL); and C) IGFBP-3 (μg/mL). Bars are the means and SD. Data were analyzed by two-way analyses (cocaine use [cocaine group and control group] and sex [women and men]).

doi:10.1371/journal.pone.0118610.g001
Correlation analyses were performed between plasma concentrations of BDNF, IGF-1 or IGFBP-3 and age for each study group, as shown in Fig. 2. The plasma IGF-1 concentrations were negatively correlated with age in the cocaine ($r = -0.33, p < 0.001$) and control ($r = -0.32, p < 0.001$) groups using the Pearson’s correlation coefficient for normal distributions. These correlations were not significant for BDNF and IGFBP-3 concentrations.

**Figure 2**

![Correlation analyses between plasma concentrations of BDNF, IGF-1 and IGFBP-3 and age in abstinent cocaine users (black circles) and control subjects (white circles). A) BDNF (pg/mL); B) IGF-1 (ng/mL); and C) IGFBP-3 (μg/mL). Dots are individual values. (r) Pearson’s correlation coefficient; (rho) Spearman’s correlation coefficient; (p) p-value for statistical significance.](doi:10.1371/journal.pone.0118610.g002)
3 Multiple correlation analyses of BDNF, IGF-1 and IGFBP-3 with other plasma molecules sensitive to cocaine addiction

We determined the degree of association among these peptides (BDNF, IGF-1 and IGFBP-3) and other plasma mediators in the cocaine and control groups. Recently, we have reported that certain circulating pro-inflammatory mediators and fatty acid derivatives are influenced by cocaine addiction [12,13]. Thus, we examined the degree of association of BDNF, IGF-1 and IGFBP-3 with these molecules and among themselves in the sample. The significances of the resulting correlation coefficients were statistically corrected using the Holm-Bonferroni method to counteract the problem of multiple comparisons for the control and cocaine groups.

3.1 BDNF. Plasma concentrations of BDNF showed a non-normal distribution in abstinent cocaine subjects and controls and the correlation coefficients calculated were rho (Table 2).

In the cocaine group, BDNF concentrations did not correlate with the concentrations of chemokines (CX3CL1, CCL2 and CXCL12), cytokines (IL1β, TNFα, IL6 and IL10), fatty acid derivatives (N-acyl-ethanolamines and 2-acyl-glycerols), IGF-1 or IGFBP-3. In contrast, BDNF concentrations correlated positively with the concentrations of certain chemokines and N-acyl-ethanolamines in the control group. Concretely, BDNF significantly correlated with CX3CL1 (rho = +0.69, adjusted p < 0.001) and CXCL12 (rho = +0.78, adjusted p < 0.001); PEA

Table 2. Multiple correlations between plasma concentrations of BDNF and other plasma molecules in the cocaine group.

| VARIABLE                  | COCAINE | BDNF | CONTROL |
|---------------------------|---------|------|---------|
|                           | rho     | p-value | adjusted p-value | rho     | p-value | adjusted p-value |
| CX3CL1 (fractalkine)     | -0.094  | 0.441 ns |               | +0.693  | <0.001 | <0.001       |
| CCL2 (MCP-1)             | -0.005  | 0.968 ns |               | +0.009  | 0.941   | ns           |
| CXCL12 (SDF-1)           | -0.110  | 0.363 ns |               | +0.784  | <0.001 | <0.001       |
| IL1β                     | -0.109  | 0.372 ns |               | -0.135  | 0.269   | ns           |
| TNFα                     | -0.133  | 0.272 ns |               | -0.189  | 0.120   | ns           |
| IL6                      | -0.260  | 0.029 ns |               | +0.054  | 0.660   | ns           |
| IL10                     | -0.110  | 0.365 ns |               | +0.031  | 0.799   | ns           |
| SEA                      | -0.047  | 0.695 ns |               | +0.325  | 0.007   | ns           |
| PEA                      | -0.058  | 0.629 ns |               | +0.492  | <0.001 | 0.003        |
| OEA                      | -0.133  | 0.270 ns |               | +0.400  | <0.001 | 0.033        |
| POEA                     | -0.037  | 0.760 ns |               | +0.331  | 0.006   | ns           |
| AEA                      | -0.150  | 0.213 ns |               | +0.447  | <0.001 | 0.005        |
| LEA                      | -0.187  | 0.119 ns |               | +0.423  | <0.001 | 0.014        |
| DGLEA                    | -0.170  | 0.156 ns |               | +0.524  | <0.001 | 0.002        |
| DHEA                     | +0.009  | 0.938 ns |               | +0.301  | 0.012   | ns           |
| 2-AG                     | +0.074  | 0.538 ns |               | +0.054  | 0.661   | ns           |
| 2-LG                     | -0.056  | 0.640 ns |               | +0.122  | 0.320   | ns           |
| IGF-1                    | -0.157  | 0.210 ns |               | -0.111  | 0.291   | ns           |
| IGFBP-3                  | -0.170  | 0.156 ns |               | -0.221  | 0.106   | ns           |

1 All variables were assessed for normality to select the adequate correlation coefficient (r; rho).
2 Adjusted p-values were calculated using Holm-Bonferroni correction (3x18 correlations per group).

Abbreviations: ns, non-significant.
(r = +0.49, adjusted p<0.01), OEA (r = +0.40, adjusted p<0.05), AEA (r = +0.45, adjusted p<0.01), LEA (r = +0.42, adjusted p<0.05) and DGLEA (r = +0.52, adjusted p<0.01). Although BDNF was initially associated with other N-acyl-ethanolamines (SEA, POEA and DHEA), the statistical adjustment for multiple comparisons rejected them.

3.2 IGF-1. Plasma concentrations of IGF-1 were normally distributed in the cocaine and control groups and Pearson’s correlation coefficients (r) were calculated for all comparisons. As shown in Table 3, IGF-1 concentrations did not correlate with the concentrations of the plasma molecules that were assessed in the cocaine group. Only we found an initial association with its binding protein IGFBP-3 prior to apply the correction test that was rejected. However, in the control group this positive correlation between the concentrations of IGF-1 and IGFBP-3 was significant after adjusting the significance (r = +0.46, adjusted p<0.01). Similar to BDNF, IGF-1 showed correlations with some N-acyl-ethanolamines (PEA and OEA) that were also discarded after correcting them.

3.3 IGFBP-3. As indicated in Table 4, IGFBP-3 concentrations passed the normality test in both groups and Pearson’s correlation coefficients (r) were calculated. In the cocaine group, plasma concentrations of IGFBP-3 were not associated with the plasma mediators that were examined with the exception of SEA. Thus, plasma concentrations of IGFBP-3 correlated positively with SEA (r = +0.40; adjusted p<0.05). Regarding control subjects, IGFBP-3 concentrations were not correlated with the rest of molecules although some positive

Table 3. Multiple correlations between plasma concentrations of IGF-1 and other plasma molecules in the cocaine group.

| VARIABLE | COCAINE | IGF-1 |
|----------|---------|-------|
|          | r       | p-value | adjusted p-value | r       | p-value | adjusted p-value |
| CX3CL1 (fractalkine) | -0.062 | 0.608 ns | | -0.062 | 0.792 ns | |
| CCL2 (MCP-1) | +0.087 | 0.472 ns | | +0.087 | 0.137 ns | |
| CXCL12 (SDF-1) | +0.013 | 0.914 ns | | +0.013 | 0.845 ns | |
| IL1β | +0.067 | 0.582 ns | | +0.067 | 0.180 ns | |
| TNFα | +0.048 | 0.693 ns | | +0.048 | 0.638 ns | |
| IL6 | +0.078 | 0.519 ns | | +0.078 | 0.520 ns | |
| IL10 | +0.089 | 0.462 ns | | +0.089 | 0.799 ns | |
| SEA | +0.086 | 0.436 ns | | +0.086 | 0.187 ns | |
| PEA | +0.054 | 0.624 ns | | -0.281 | 0.019 ns | |
| OEA | -0.064 | 0.560 ns | | -0.264 | 0.028 ns | |
| POEA | -0.142 | 0.195 ns | | +0.006 | 0.964 ns | |
| AEA | -0.085 | 0.437 ns | | -0.186 | 0.125 ns | |
| LEA | -0.095 | 0.387 ns | | -0.133 | 0.275 ns | |
| DGLEA | -0.018 | 0.873 ns | | -0.184 | 0.131 ns | |
| DHEA | +0.171 | 0.118 ns | | -0.309 | 0.010 ns | |
| 2-AG | -0.120 | 0.275 ns | | -0.097 | 0.430 ns | |
| 2-LG | -0.074 | 0.503 ns | | -0.119 | 0.331 ns | |
| IGFBP-3 | +0.327 | 0.006 ns | | +0.463 | <0.001 | 0.003 |

1 All variables were assessed for normality to select the adequate correlation coefficient (r; rho).
2 Adjusted p-values were calculated using Holm-Bonferroni correction (3x18 correlations per group).
Abbreviations: ns, non-significant.

doi:10.1371/journal.pone.0118610.t003
associations were observed in paired-comparisons with cytokines (IL1β, IL6 and IL10) without adjustment for multiple comparisons.

Overall, while BDNF concentrations correlated positively with chemokines and N-acyl-ethanolamines in the control group, IGFBP-3 was found to be positively associated only with SEA in the cocaine group. Moreover, IGF-1 and IGFBP-3 correlated positively in the control group but not in the cocaine group.

### 4 Plasma concentrations of BDNF, IGF-1 and IGFBP-3 in relation to variables associated with cocaine use

In the cocaine group, correlation analyses were performed between plasma concentrations of BDNF, IGF-1 or IGFBP-3 and length of cocaine abstinence (days) and duration of cocaine use (years) (S1 Fig.). Because both length of cocaine abstinence and duration of cocaine were variables with a non-normal distribution, Spearman’s rank correlation coefficients (rho) were used for determining associations. However, we observed no correlations between these mediators and variables related to abstinence and cocaine use.

Additional correlation analyses were performed between plasma concentrations of BDNF, IGF-1 or IGFBP-3 and individual scores of DSM-IV-TR criteria for cocaine abuse and dependence. The concentrations of these peptides were not associated with the cocaine symptom severity (S2 Fig.). As expected, the cocaine group displayed an increased number of criteria for cocaine use disorders (7.3±3.3 criteria) which indicates a high cocaine symptom severity.

| VARIABLE | COCAINE | IGFBP-3 |
|----------|---------|---------|
|          | r       | p-value | adjusted p-value | r       | p-value | adjusted p-value |
| CX3CL1 (fractalkine) | -0.006 | 0.963 | ns | +0.113 | 0.356 | ns |
| CCL2 (MCP-1) | +0.126 | 0.303 | ns | +0.171 | 0.159 | ns |
| CXCL12 (SDF-1) | -0.113 | 0.357 | ns | +0.141 | 0.250 | ns |
| IL1β | -0.062 | 0.611 | ns | +0.317 | 0.008 | ns |
| TNFα | -0.047 | 0.699 | ns | +0.233 | 0.054 | ns |
| IL6 | +0.067 | 0.587 | ns | +0.321 | 0.007 | ns |
| IL10 | -0.052 | 0.672 | ns | +0.244 | 0.044 | ns |
| SEA | +0.397 | <0.001 | 0.011 | -0.091 | 0.459 | ns |
| PEA | +0.216 | 0.058 | ns | -0.048 | 0.696 | ns |
| OEA | -0.226 | 0.056 | ns | +0.115 | 0.348 | ns |
| POEA | -0.121 | 0.272 | ns | +0.046 | 0.710 | ns |
| AEA | -0.079 | 0.473 | ns | +0.125 | 0.307 | ns |
| LEA | +0.038 | 0.732 | ns | -0.003 | 0.979 | ns |
| DGLEA | -0.084 | 0.446 | ns | +0.006 | 0.963 | ns |
| DHEA | +0.042 | 0.707 | ns | +0.079 | 0.521 | ns |
| 2-AG | +0.010 | 0.926 | ns | +0.145 | 0.235 | ns |
| 2-LG | -0.093 | 0.398 | ns | +0.132 | 0.280 | ns |

1 All variables were assessed for normality to select the adequate correlation coefficient (r; rho).
2 Adjusted p-values were calculated using Holm-Bonferroni correction (3x18 correlations per group).

Abbreviations: ns, non-significant.

doi:10.1371/journal.pone.0118610.t004
Psychiatric comorbidity and substance use disorders

Because all outpatient cocaine users display high rates of comorbid psychiatric disorders, we evaluated plasma concentrations of BDNF, IGF-1 and IGFBP-3 in the most common psychiatric comorbidities among substance users, as shown in Table 5.

The DSM-IV-TR Axis I disorders included mood disorders, anxiety and psychosis. Considering the exclusive diagnoses, the prevalences of cocaine-induced mood and psychotic (18.0% and 11.0% respectively) disorders were higher than the primary mood and psychotic (11.0% and 2.0% respectively) disorders, unlike cocaine-induced and primary anxiety disorders (7.0% and 12.0% respectively). Also, some cocaine users were diagnosed with both primary and cocaine-induced mood (n = 5) and anxiety (n = 3) disorders. With respect to personality disorders, the prevalence reached a 31.0%.

Considering the plasma concentrations of BDNF, IGF-1 and IGFBP-3 in these outpatient users diagnosed with psychiatric comorbidities, we only observed significant changes in BDNF concentrations. Concretely, abstinent cocaine users diagnosed with both primary and cocaine-induced disorders (for mood or anxiety disorders) displayed significant decreases in plasma BDNF concentrations (p < 0.05) compared to those users with no mood disorders or no anxiety. Additionally, the decrease in BDNF concentrations in subjects diagnosed with both primary and cocaine-induced anxiety disorders were also significant (p < 0.05) relative to the control group.

Table 5. Plasma concentrations of BDNF, IGF-1 and IGFBP-3 in abstinent cocaine users grouped by diagnosis of common psychiatric disorders in substance users.

| VARIABLE | n (%) | BDNF pg/mL [mean (SD)] | IGF-1 ng/mL [mean (SD)] | IGFBP-3 μg/mL [mean (SD)] |
|----------|-------|-----------------------|-------------------------|---------------------------|
| MOOD DISORDERS¹ | 33 (33.0) | 240.2 (177.4) | 213.1 (83.4) | 3.83 (0.99) |
| Primary | 11 (11.0) | 297.0 (223.2) | 246.4 (59.7) | 4.31 (0.73) |
| Cocaine-induced | 17 (18.0) | 227.6 (150.4) | 196.5 (91.8) | 3.83 (1.07) |
| Primary & Cocaine-induced | 5 (5.0) | 131.8 (66.7) ⁴ | 186.5 (38.8) | 3.30 (0.67) |
| NO MOOD DISORDERS | 67 (67.0) | 294.9 (211.4) | 210.8 (52.5) | 3.87 (0.92) |
| ANXIETY DISORDERS | 22 (22.0) | 268.2 (171.1) | 191.6 (61.9) | 3.80 (0.91) |
| Primary | 12 (12.0) | 278.9 (170.0) | 182.3 (67.6) | 3.84 (0.87) |
| Cocaine-induced | 7 (7.0) | 293.6 (199.3) | 199.9 (67.2) | 4.11 (1.09) |
| Primary & Cocaine-induced | 3 (3.0) | 137.9 (9.0) ⁵, * | 209.8 (16.0) | 3.16 (0.75) |
| NO ANXIETY DISORDERS | 78 (78.0) | 276.8 (208.9) | 217.1 (63.7) | 3.94 (0.95) |
| PSYCHOTIC DISORDERS | 13 (13.0) | 262.9 (209.9) | 206.7 (59.3) | 3.83 (0.84) |
| Primary | 2 (2.0) | 163.4 (168.1) | 178.5 (0.0) | 3.49 (0.30) |
| Cocaine-induced | 11 (11.0) | 281.0 (218.4) | 211.0 (62.9) | 3.89 (0.90) |
| NO PSYCHOTIC DISORDERS | 87 (87.0) | 277.2 (199.9) | 213.0 (64.8) | 3.92 (0.95) |
| PERSONALITY DISORDERS (CLUSTER-B)² | 31 (31.0) | 232.8 (176.8) | 197.0 (64.5) | 3.83 (0.91) |
| NO PERSONALITY DISORDERS | 69 (69.0) | 294.5 (208.9) | 218.1 (63.4) | 3.94 (0.95) |
| CONTROL GROUP | 269.4 (242.7) | 210.7 (51.2) | 3.78 (0.93) |

¹ Mood disorders include major depressive disorder, dysthymic disorder, bipolar disorders (mania and hypomania) and cocaine-induced mood disorders.

² Cluster B personality disorders include borderline and antisocial personality disorders.

ᵃ p < 0.05 denotes significant differences compared to the no mood disorders subgroup.

ᵇ p < 0.05 denotes significant differences compared to the no anxiety disorders subgroup.

* p < 0.05 denotes significant differences compared to the control group.

doi:10.1371/journal.pone.0118610.t005

5 Psychiatric comorbidity and substance use disorders

Because all outpatient cocaine users display high rates of comorbid psychiatric disorders, we evaluated plasma concentrations of BDNF, IGF-1 and IGFBP-3 in the most common psychiatric comorbidities among substance users, as shown in Table 5.

The DSM-IV-TR Axis I disorders included mood disorders, anxiety and psychosis. Considering the exclusive diagnoses, the prevalences of cocaine-induced mood and psychotic (18.0% and 11.0% respectively) disorders were higher than the primary mood and psychotic (11.0% and 2.0% respectively) disorders, unlike cocaine-induced and primary anxiety disorders (7.0% and 12.0% respectively). Also, some cocaine users were diagnosed with both primary and cocaine-induced mood (n = 5) and anxiety (n = 3) disorders. With respect to personality disorders, the prevalence reached a 31.0%.

Considering the plasma concentrations of BDNF, IGF-1 and IGFBP-3 in these outpatient users diagnosed with psychiatric comorbidities, we only observed significant changes in BDNF concentrations. Concretely, abstinent cocaine users diagnosed with both primary and cocaine-induced disorders (for mood or anxiety disorders) displayed significant decreases in plasma BDNF concentrations (p < 0.05) compared to those users with no mood disorders or no anxiety. Additionally, the decrease in BDNF concentrations in subjects diagnosed with both primary and cocaine-induced anxiety disorders were also significant (p < 0.05) relative to the control group.
Regarding IGF-1 and IGFBP-3, we observed no changes in their plasma concentrations by the presence of psychiatric comorbidities.

**Discussion**

The present exploratory and cross-sectional study found that the plasma concentrations of BDNF and IGF-1 are unaltered by a lifetime pathological use of cocaine in abstinent cocaine users under treatment. Indeed, plasma concentrations of these factors were not influenced by the length of abstinence, duration of cocaine use or cocaine symptom severity. The association of plasma IGF-1 concentrations with age was not affected by the pathological use of cocaine, although the association of IGF-1 and IGFBP-3 did not reach statistical significance after correcting it in abstinent cocaine users. Additionally, the correlations of BDNF concentrations with chemokines and N-acyl-ethanolamines in the control group were not observed in cocaine subjects. However, we detected a positive correlation between the concentrations of IGFBP-3 and SEA in the cocaine group. On the other hand, we found an elevated prevalence of comorbid psychiatric disorders in these patients with polysubstance use and changes in BDNF concentrations related to the diagnosis of mood and anxiety disorders. Thus, plasma BDNF concentrations were reduced in cocaine users diagnosed with both primary and cocaine-induced mood and anxiety disorders.

**BDNF in abstinent cocaine users**

Although we found no changes in BDNF concentrations, several clinical studies have reported changes in the serum BDNF concentrations of cocaine dependents during abstinence, suggesting that BDNF is a reliable biomarker for cocaine addiction. A first study in cocaine dependent individuals found that BDNF concentrations are increased during early abstinence, and the elevated BDNF is predictive of relapse risk during early recovery from cocaine dependence [16]. Related to this finding, another study reported that BDNF concentrations are positively correlated with cocaine craving and abstinence symptoms [17]. Similarly, more recent studies in crack cocaine dependent individuals have found high blood BDNF concentrations during early abstinence [36] and negative correlations with severity [37] and amount of cocaine used [38]. All these prospective studies were conducted in cocaine addicts following inpatient detoxification treatments during 2–4 weeks, unlike our study that is a cross-sectional study in cocaine users seeking treatment in outpatient programs. Consequently, we have a single measure for BDNF from each cocaine user, variable periods of abstinence and uncontrolled environmental factors (inherent in outpatient treatments) that may be interfering with the present data.

**IGF-1 and IGFBP-3 in abstinent cocaine users**

Numerous studies in mammals have reported that IGF-1 concentrations decline with advancing age, showing the association of IGF-1 with longevity and age-related diseases (e.g., cancer, cardiovascular disease, diabetes, osteoporosis, and neurodegenerative diseases) [39,40,41]. We observed that IGF-1 concentrations correlated significantly with the age of the participants. According to the present results, the history of a pathological use of cocaine did not influence the association of IGF-1 concentrations and aging because the significant and negative correlation between both variables was identical to the control group. However, we did not evaluated the cognitive impairment in the sample [42].

Focusing on cocaine addiction, we observed no changes in the plasma concentrations of IGF-1 and IGFBP-3 of abstinent users and concentrations did not correlated with addiction-related variables such as severity cocaine symptom, abstinence or duration of cocaine use. We did not find literature about an association between IGF-1 and cocaine but other drugs of
abuse have been investigated. Studies in rodents suggest that IGF-1 is altered in cerebral areas related to the development of addiction after chronic exposure to morphine [43,44]. In humans, a recent study in patients with opiate use dependence has demonstrated that serum IGF-1 is elevated [5]. In addition to opiates, various studies evaluating IGF-1 have been conducted in alcohol dependent subjects but the authors did not observe any interaction between alcohol addiction and this peptide in blood or brain [25,45]. However, a recent study in alcohol dependent patients has found that IGF-1 might play a role in the cognitive function in these subjects [46].

Lack of association with biomarkers of cocaine addiction

Overall, the lack of influence of cocaine addiction on plasma concentrations of BDNF and IGF-1 was confirmed through multiple analyses of correlation coefficients of these factors with other circulating molecules sensitive to cocaine addiction and/or psychiatric comorbidity in cocaine abstinent subjects from similar observational studies [12,13]. Chemokines and pro-inflammatory mediators are affected by the cocaine symptom severity, while anti-inflammatory fatty acid derivatives such as endocannabinoids and their congeners are affected by the history of pathological use of cocaine and the presence of comorbid disorders. Thus, the significant correlations between these cocaine-sensitive molecules and BDNF and IGF-1 (and IGFBP-3) in controls vanished in the cocaine group. However, we observed only one significant correlation after multiple comparisons in the cocaine group, in particular IGFBP-3 and SEA concentrations, but the SEA concentrations is not affected by cocaine use unlike other N-acyl-ethanolamines [13].

Because IGF-1 forms a ternary complex with IGFBP-3 [47], we also studied the association between both peptides. We detected a positive correlation between plasma concentrations of IGF-1 and IGFBP-3 in the control participants, but such association was weakly affected by the lifetime pathological use of cocaine.

BDNF and IGF-1 in abstinent cocaine users with psychiatric comorbidity

Similar to these previous cross-sectional studies in abstinent cocaine users recruited from outpatient programs, we have detected a high prevalence of comorbid psychiatric disorders, approximately 60% [12,13]. Although these plasma peptide concentrations were unaltered in cocaine users, we examined these concentrations according to the diagnosis of primary and cocaine-induced disorders. Substantial evidence indicates neurotrophic/growth factors such as BDNF and IGF-1 are involved in the pathogenesis of common psychiatric disorders. We have indeed observed in this study changes in circulating concentrations of these neurotrophic factors in mood and anxiety disorders, especially in BDNF.

BDNF in psychiatric comorbidity

Current literature on BDNF and mental disorders is particularly focused on depressive and bipolar disorders. Thus, circulating concentrations of BDNF are decreased in depressed patients compared to controls and that they increase significantly with antidepressant treatment [48,49,50]. The reduction of plasma BDNF concentration has also been related to suicidal behavior in major depression [51] whereas other studies in bipolar patients have found a significant association with the severity of depression [52,53], suggesting that plasma BDNF concentrations may be a marker of depression and/or bipolar disorder. Our findings are consistent with the literature because BDNF concentrations in cocaine users diagnosed with mood disorders, both primary and cocaine-induced, were found to be decreased. However, only five cocaine users were identified with this complicated diagnosis and, therefore, the statistical
significance of this reduction may be called into question. We observed no differences in the BDNF concentrations of those abstinent subjects displaying primary mood disorders or cocaine-induced mood disorders separately.

BDNF has also emerged as a potential biomarker for anxiety from preclinical studies in rodents [54]. Translational studies have reported that early stress correlates negatively with peripheral BDNF concentrations later in life [55]. A recent review of clinical studies showed that BDNF concentrations were lower in individuals with any anxiety disorder compared to those without anxiety but this is not consistent across the literature [56]. In support of this, abstinent cocaine users diagnosed with both primary and cocaine-induced anxiety disorders exhibited a significant decrease in plasma BDNF, as seen previously with mood disorders. Again, the main limitation of this observation is related to the reduced number of individuals with this dual (primary and cocaine-induced anxiety) comorbid diagnosis.

**IGF-1 in psychiatric comorbidity**

Several studies in old and young populations have shown the association between IGF-1 concentrations and depressive symptoms [23,24]. It has been reported that plasma IGF-1 concentrations are increased in acute depressed patients [57] and similarly, another study demonstrated that patients with bipolar disorder have elevated IGF-1 concentrations [58]. Although our data are consistent with these observations and cocaine users with primary mood disorders displayed an increase in plasma IGF-1 and IGFBP-3 concentrations, these increases did not reach statistical significance relative to the control group and abstinent users without mood disorders.

We need to perform additional studies to establish the mechanisms of action of these trophic factors (especially BDNF) and the selectivity in the influence of each factor by a specific comorbid disorder in cocaine addiction.

**Limitations and future perspectives**

Although our findings support the importance of monitoring BDNF and IGF-1 in the context of cocaine addiction with psychiatric comorbidity, we are aware of the limitations of the present exploratory study. Firstly, the number of cases reported in our study with comorbid disorders is small and the replication is necessary. We cannot conclude whether these changes in BDNF and IGF-1 concentrations are exclusive to cocaine addiction or not because new studies in psychiatric patients with no history of drug use will be necessary to elucidate their role in mental disorders. Additional studies to determine plasma BDNF and IGF-1 in active cocaine users are necessary to confirm the lack of effects produced by the presence of cocaine on circulating concentrations of these factors. Further, longitudinal studies during cocaine abstinence could indicate whether these concentrations are unaltered or time-dependent.

The present study was conducted on outpatient subjects and, therefore we tried to show a realistic example of individuals seeking treatment in public centers for addiction but without being isolated from their social and familiar context. Nevertheless, from our results, we believe that monitoring neurotrophic factors such as BDNF and IGF-1 in cocaine users seeking treatment remains to be investigated to further improve the stratification of these patients taking into consideration the psychiatric comorbidities.

**Supporting Information**

S1 Fig. Correlation analyses between plasma concentrations of BDNF, IGF-1 and IGFBP-3 and variables related to addiction: length of abstinence and amount of cocaine use in abstinent cocaine users. A) BDNF (pg/mL); B) IGF-1 (ng/mL); and C) IGFBP-3 (μg/mL). Black
dots are individual values. (r) Pearson’s correlation coefficient; (rho) Spearman’s correlation coefficient; (p) p-value for statistical significance.

(S2 Fig. Correlation analyses between plasma concentrations of BDNF, IGF-1 and IGFBP-3 and total number of DSM-IV-TR criteria for cocaine abuse and dependence in abstinent cocaine users. A) BDNF (pg/mL); B) IGF-1 (ng/mL); and C) IGFBP-3 (μg/mL). Black dots are individual values. (rho) Spearman’s correlation coefficient; (p) p-value for statistical significance.

Author Contributions
Conceived and designed the experiments: FRF FJP. Performed the experiments: MP NG-M PA RC-C JJR PR-S AS JS EC-O FJP VB JAC JA AIM-V MAV FRF. Analyzed the data: LJS FRF FJP. Contributed reagents/materials/analysis tools: MT RdT LJS. Wrote the paper: FJP FRF. Were responsible for the study concept and design: FRF FJP. Coordinated and recruited participants from Outpatient Treatment Centers in Málaga: MP NG-M PA RC-C JJR. Contributed to the acquisition of psychiatric data by means of interviews: MP PA NG-M PR-S. Obtained and processed blood samples: AS JS EC-O FJP. Supervised the benzoylecgonine detection and supervised the quantification of acyl derivatives in plasma: RdT. Supervised and performed the quantification of cytokines, chemokines and BDNF from human plasma: VB JAC JA. Supervised and performed the quantification of IGF-1 and IGFBP-3 from human plasma: AIM-V MAV. Assisted with data analysis and interpretation of findings: LJS FRF FJP. Drafted the manuscript: FRF FJP. Provided critical revision of the manuscript for important intellectual content: MT RdT LJS VB MAV. Critically reviewed content and approved final version for publication: All authors.

References
1. Thomas MJ, Kalivas PW, Shaham Y. Neuroplasticity in the mesolimbic dopamine system and cocaine addiction. Br J Pharmacol. 2008; 154: 327–342. doi: 10.1038/bjp.2008.77 PMID: 18345022
2. Haile CN, Mahoney JJ 3rd, Newton TF, De La Garza R 2nd. Pharmacotherapeutics directed at deficiencies associated with cocaine dependence: focus on dopamine, norepinephrine and glutamate. Pharmacol Ther. 2012; 134: 260–277. doi: 10.1016/j.pharmthera.2012.01.010 PMID: 22327234
3. Robinson TE, Kolb B. Structural plasticity associated with exposure to drugs of abuse. Neuphemropsychology. 2004; 47 Suppl 1: 33–46. PMID: 15464124
4. Herrero MJ, Domingo-Salvany A, Torrens M, Brugal MT. Psychiatric comorbidity in young cocaine users: induced versus independent disorders. Addiction. 2008; 103: 284–293. doi: 10.1111/j.1360-0443.2007.02076.x PMID: 18199307
5. Reece AS. Elevated IGF1 in clinical opiate dependence. Neuro Endocrinol Lett. 2013; 34: 18–26. PMID: 23524620
6. Araos P, Vergara-Moragues E, Pedraz M, Pavon FJ, Campos Cloute R, Calado M, et al. [Psychopathological comorbidity in cocaine users in outpatient treatment]. Adicciones. 2014; 26: 15–26. PMID: 24652395
7. Torrens M, Serrano D, Astals M, Perez-Dominguez G, Martin-Santos R. Diagnosing comorbid psychiatric disorders in substance abusers: validity of the Spanish versions of the Psychiatric Research Interview for Substance and Mental Disorders and the Structured Clinical Interview for DSM-IV. Am J Psychiatry. 2004; 161: 1231–1237. PMID: 15229056
8. Torrens M, Martin-Santos R, Samet S. Importance of clinical diagnoses for comorbidity studies in substance use disorders. Neurotox Res. 2006; 10: 253–261. PMID: 17187374
9. Domenici E, Wille DR, Tozzi F, Prokopenko I, Miller S, McKeown A, et al. Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. PLoS One. 2010; 5: e9166. doi: 10.1371/journal.pone.0009166 PMID: 20161799
10. Sinha R. New findings on biological factors predicting addiction relapse vulnerability. Curr Psychiatry Rep. 2011; 13: 398–405. doi: 10.1007/s11920-011-0224-0 PMID: 21792580

11. Domenci E, Muglia P. The search for peripheral disease markers in psychiatry by genomic and proteomic approaches. Expert Opin Med Diagn. 2007; 1: 235–251. doi: 10.1517/17530059.1.2.235 PMID: 23489310

12. Araos P, Pedraz M, Serrano A, Lucena M, Barrios V, Garcia-Marchena N, et al. Plasma profile of pro-inflammatory cytokines and chemokines in cocaine users under outpatient treatment: influence of cocaine symptom severity and psychiatric co-morbidity. Addict Biol. 2014 May 22. doi: 10.1111/adb.12156

13. Pavon FJ, Araos P, Pastor A, Calado M, Pedraz M, Campos-Cloute R, et al. Evaluation of plasma-free endocannabinoids and their congeners in abstinent cocaine addicts seeking outpatient treatment: impact of psychiatric co-morbidity. Addict Biol. 2013; 18: 955–969. doi: 10.1111/adb.12107 PMID: 24283982

14. Castren E. Neurotrophins as mediators of drug effects on mood, addiction, and neuroprotection. Mol Neurobiol. 2004; 29: 289–302. PMID: 15181240

15. Corominas-Roso M, Ramos-Quiroga JA, Ribases M, Sanchez-Mora C, Palomar G, Valero S, et al. Decreased serum levels of brain-derived neurotrophic factor in adults with attention-deficit hyperactivity disorder. Int J Neuropsychopharmacol. 2013; 1–9. doi: 10.1017/S1461145713000746 PMID: 23953038

16. D’Sa C, Fox HC, Hong AK, Dileone RJ, Sinha R. Increased serum brain-derived neurotrophic factor is predictive of cocaine relapse outcomes: a prospective study. Biol Psychiatry. 2011; 70: 706–711. doi: 10.1016/j.biopsych.2011.05.013 PMID: 21741029

17. Corominas-Roso M, Roncero C, Eiroa-Orosa FJ, Goncalo B, Grau-Lopez L, Ribases M, et al. Brain-derived neurotrophic factor serum levels in cocaine-dependent patients during early abstinence. Eur Neuropsychopharmacol. 2013; 23: 1078–1084. doi: 10.1016/j.euroenceuro.2012.08.016 PMID: 23021567

18. Corominas-Roso M, Roncero C, Eiroa-Orosa FJ, Ribases M, Barral C, Daigre C, et al. Serum brain-derived neurotrophic factor levels and cocaine-induced transient psychotic symptoms. Neuropsychobiology. 2013; 68: 146–155. doi: 10.1159/000353259 PMID: 24051573

19. O’Kusky J, Ye P. Neurodevelopmental effects of insulin-like growth factor signaling. Front Neuroendocrinol. 2012; 33: 230–251. doi: 10.1016/j.yfrne.2012.06.002 PMID: 22710100

20. Torres-Aleman I. Toward a comprehensive neurobiology of IGF-I. Dev Neurobiol. 2010; 70: 384–396. doi: 10.1002/dneu.20778 PMID: 20186710

21. Malberg JE, Platt B, Rizzo SJ, Ring RH, Lucki I, Schechter LE, et al. Increasing the levels of insulin-like growth factor-I by an IGF binding protein inhibitor produces anxiolytic and antidepressant-like effects. Neuropsychopharmacology. 2007; 32: 2360–2368. PMID: 17342171

22. Trueba-Saiz A, Cavada C, Fernandez AM, Leon T, Gonzalez DA, Fortea Ormaechea J, et al. Loss of serum IGF-I input to the brain as an early biomarker of disease onset in Alzheimer mice. Transl Psychiatry. 2013; 3: e330. doi: 10.1038/tp.2013.102 PMID: 24301648

23. Lin F, Suhr J, Diebold S, Heftner KL. Associations between depressive symptoms and memory deficits vary as a function of insulin-like growth factor (IGF-1) levels in healthy older adults. Psychoneuroendocrinology. 2014; 42: 118–123. doi: 10.1016/j.psyneuen.2014.01.006 PMID: 24636508

24. Stouthart PJ, Deien JB, Roffel M, Delemarre-van de Waal HA. Quality of life of growth hormone (GH) deficient young adults during discontinuation and restart of GH therapy. Psychoneuroendocrinology. 2003; 28: 612–626. PMID: 12727130

25. Leggio L, Ferrulli A, Malandrino N, Miceli A, Capristo E, Gasbarrini G, et al. Insulin but not insulin growth factor-1 correlates with craving in currently drinking alcohol-dependent patients. Alcohol Clin Exp Res. 2008; 32: 450–458. doi: 10.1111/j.1530-0277.2007.00589.x PMID: 18215216

26. Hasin DS, Trautman KD, Miele GM, Samet S, Smith M, Endicott J. Psychiatric Research Interview for Substance and Mental Disorders (PRISM): reliability for substance abusers. Am J Psychiatry. 1996; 153: 1195–1201. PMID: 8780425

27. Robins LN, Wing J, Wittchen HU, Helzer JE, Babor TF, Burke J, et al. The Composite International Diagnostic Interview—an Epidemiologic Instrument Suitable for Use in Conjunction with Different Diagnostic Systems and in Different Cultures. Archives of General Psychiatry.1988; 45: 1069–1077. PMID: 2848472

28. Hasin D, Samet S, Nunes E, Meydan J, Matseoa K, Waxman R. Diagnosis of comorbid psychiatric disorders in substance users assessed with the Psychiatric Research Interview for Substance and Mental Disorders for DSM-IV. Am J Psychiatry. 2006; 163: 689–696. PMID: 16585445
29. Morgello S, Holzer CE 3rd, Ryan E, Young C, Naseer M, Castellon SA, et al. Interrater reliability of the Psychiatric Research Interview for Substance and Mental Disorders in an HIV-infected cohort: experience of the National NeuroAIDS Tissue Consortium. Int J Methods Psychiatr Res. 2006; 15: 131–138. PMID: 17019897
30. Hasin DS, Fenton MC, Beseler C, Park JY, Wall MM. Analyses related to the development of DSM-5 criteria for substance use related disorders: 2. Proposed DSM-5 criteria for alcohol, cannabis, cocaine and heroin disorders in 663 substance abuse patients. Drug Alcohol Depend. 2012; 122: 28–37. doi: 10.1016/j.drugalcdep.2011.09.005 PMID: 21963333
31. Hasin DS, O’Brien CP, Auriacombe M, Borges G, Bucholz K, Budney A, et al. DSM-5 criteria for substance use disorders: recommendations and rationale. Am J Psychiatry. 2013; 170: 834–851. doi: 10.1176/appi.ajp.2013.12060782 PMID: 23903334
32. Rivera P, Luque-Rojas MJ, Pastor A, Blanco E, Pavon FJ, Serrano A, et al. Diet-dependent modulation of hippocampal expression of endocannabinoid signaling-related proteins in cannabinoid antagonist-treated obese rats. Eur J Neurosci. 2013; 37: 105–117. doi: 10.1111/ejn.12012 PMID: 23939077
33. Guevara-Aguirre J, Balalasubramanian P, Guevara-Aguirre M, Wei M, Madia F, Cheng CW, et al. Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Sci Transl Med. 2011; 3: 70ra13. doi: 10.1126/scitranslmed.3001845 PMID: 21252617
34. Pawlikowska L, Hu D, Huntsman S, Sung A, Chu C, Chen J, et al. Association of common genetic variation in the insulin/IGF-I signaling pathway with human longevity. Aging Cell. 2009; 8: 460–472. doi: 10.1111/j.1474-9726.2009.00493.x PMID: 19489743
35. van Heemst D, Beekman M, Mooijmans SP, Heijmans BT, Brandt BW, Zwaan BJ, et al. Reduced insulin/IGF-1 signalling and human longevity. Aging Cell. 2005; 4: 79–85. PMID: 15771611
36. Viola TW, Tractenberg SG, Levandowski ML, Pezzi JC, Bauer ME, Teixeira AL, et al. Neurotrophic factors in women with crack cocaine dependence during early abstinence: the role of early life stress. J Psychiatry Neurosci. 2014; 39: 206–214. PMID: 24331739
37. Pawlikowska L, Hu D, Huntsman S, Sung A, Chu C, Chen J, et al. Association of common genetic variation in the insulin/IGF-I signaling pathway with human longevity. Aging Cell. 2009; 8: 460–472. doi: 10.1111/j.1474-9726.2009.00493.x PMID: 19489743
38. van Heemst D, Beekman M, Mooijmans SP, Heijmans BT, Brandt BW, Zwaan BJ, et al. Reduced insulin/IGF-1 signalling and human longevity. Aging Cell. 2005; 4: 79–85. PMID: 15771611
39. Bao Q, Pan J, Qi H, Wang L, Qian H, Jiang F, et al. Aging and age-related diseases—from endocrine therapy to target therapy. Mol Cell Endocrinol. 2014; 394: 115–118. doi: 10.1016/j.mce.2014.07.005 PMID: 25098521
40. Junnilla RK, List EO, Berryman DE, Murrey JW, Kopchick JJ. The GH/IGF-1 axis in ageing and longevity. Nat Rev Endocrinol. 2013; 9: 366–376. doi: 10.1038/nrendo.2013.67 PMID: 23591370
41. Muller AP, Fernandez AM, Haas C, Zimmer E, Portela LV, Torres-Aleman I. Reduced brain insulin-like growth factor-I function during aging. Mol Cell Neurosci. 2012; 49: 9–12. doi: 10.1016/j.mcn.2011.07.008 PMID: 21807098
42. Aleman A, Torres-Aleman I. Circulating insulin-like growth factor-I and cognitive function: neuromodulation throughout the lifespan. Prog Neurobiol. 2009; 89: 256–265. doi: 10.1016/j.pneurobio.2009.07.006 PMID: 19665513
43. Hashiguchi Y, Molina PE, Fan J, Lang CH, Abumrad NN. Central opiate modulation of growth hormone and insulin-like growth factor-I. Brain Res Bull. 1996; 40: 99–104. PMID: 8724426
44. Beilnner-Johnson D, Nestler EJ. Chronic morphine decreases insulin-like growth factor-I levels in the ventral segmental area of the rat brain. Ann N Y Acad Sci. 1993; 692: 246–248. PMID: 8215026
45. Garcia-Valdecasas-Campeo E, Gonzalez-Reimers E, Santolario-Fernandez F, De La Vega-Prieto MJ, Milena-Abril A, Sanchez-Perez MJ, et al. Brain atrophy in alcoholics: relationship with alcohol intake; liver disease; nutritional status, and inflammation. Alcohol Alcohol. 2007; 42: 533–538. PMID: 17855333
46. Han C, Bae H, Kim DJ, Bae JY, Oh SI. Or12—the relationship between insulin-like growth factor-I and cognitive function in alcohol-dependent patient. Alcohol Alcohol. 2014; 49 Suppl 1: i49.
47. Hall K, Hilding A, Thoren M. Determinants of circulating insulin-like growth factor-I. J Endocrinol Invest. 1999; 22: 48–57. PMID: 10442571
48. Brunoni AR, Lopes M, Fregnari F. A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int J Neuropsychopharmacol. 2008; 11: 1169–1180. doi: 10.1017/S1461145708009309 PMID: 18752720
49. Bocchio-Chiavetto L, Bagnardi V, Zanardini R, Molteni R, Nielsen MG, Placentino A, et al. Serum and plasma BDNF levels in major depression: a replication study and meta-analyses. World J Biol Psychiatry. 2010; 11: 763–773. doi: 10.3109/15622971003611319 PMID: 20334574
50. Piccinni A, Marazziti D, Catena M, Domenici L, Del Debbio A, Bianchi C, et al. Plasma and serum brain-derived neurotrophic factor (BDNF) in depressed patients during 1 year of antidepressant treatments. J Affect Disord. 2008; 105: 279–283. PMID: 17553570
51. Kim YK, Lee HP, Won SD, Park EY, Lee HY, Lee BH, et al. Low plasma BDNF is associated with suicidal behavior in major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2007; 31: 78–85. PMID: 16904252
52. Rosa AR, Singh N, Whitaker E, de Brito M, Lewis AM, Vieta E, et al. Altered plasma glutathione levels in bipolar disorder indicates higher oxidative stress; a possible risk factor for illness onset despite normal brain-derived neurotrophic factor (BDNF) levels. Psychol Med. 2014; 1: 1–10.
53. Kenna HA, Reynolds-May M, Stepanenko A, Ketter TA, Hallmayer J, Rasgon NL. Blood levels of brain derived neurotrophic factor in women with bipolar disorder and healthy control women. J Affect Disord. 2014; 156: 214–218. doi: 10.1016/j.jad.2013.01.054 PMID: 24398043
54. Martinowich K, Manji H, Lu B. New insights into BDNF function in depression and anxiety. Nat Neurosci. 2007; 10: 1089–1093. PMID: 17726474
55. Dalle Molle R, Portella AK, Goldani MZ, Kapczinski FP, Leistner-Segal S, Salum GA, et al. Associations between parenting behavior and anxiety in a rodent model and a clinical sample: relationship to peripheral BDNF levels. Transl Psychiatry. 2012; 2: e195. doi: 10.1038/tppol.2012.126 PMID: 23168995
56. Suliman S, Hemmings SM, Seedat S. Brain-Derived Neurotrophic Factor (BDNF) protein levels in anxiety disorders: systematic review and meta-regression analysis. Front Integr Neurosci. 2013; 7: 55. doi: 10.3389/fnint.2013.00055 PMID: 23908608
57. Deuschle M, Blum WF, Strasburger CJ, Schweiger U, Weber B, Köner A, et al. Insulin-like growth factor-I (IGF-I) plasma concentrations are increased in depressed patients. Psychoneuroendocrinology. 1997; 22: 493–503. PMID: 9373883
58. Liu X, Zhang T, He S, Hong B, Chen Z, Peng D, et al. Elevated serum levels of FGF-2, NGF and IGF-1 in patients with manic episode of bipolar disorder. Psychiatry Res. 2014; 218: 54–60. doi: 10.1016/j.psychres.2014.03.042 PMID: 24793757